Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 2 sources · 17 days · First seen · Last updated
Investment in robotic biomanufacturing platforms
Overview
Recent developments in the biomanufacturing sector show increased investment in automated and optogenetics-enabled platforms.
Multiply Labs secured $75 million in Series B financing, led by Dr. Patrick Soon-Shiong and NantWorks, to scale its robotic manufacturing platform for advanced medicines such as cell and gene therapies. The company aims to use the capital to expand capacity and accelerate its product roadmap, utilizing robotic clusters designed to automate complex biologics processes.
Similarly, Prolific Machines announced new investment led by Atoms & Bits and Nant Capital to scale its optogenetics platform. This funding will support technological development for biologics, biosimilars, and viral vectors, as well as research into tissue and organ fabrication. Prolific Machines has also established strategic partnerships with Zylidac Bio to scale production of optogenetics-enabled cell lines and with NantWorks to apply its platform across various life sciences programs.
Entities
NantWorks · Prolific Machines · Zylidac Bio · Atoms & Bits · AstraZeneca
Timeline
-
[BUSINESS] 2 sourcesProlific Machines secures investment and announces partnerships
Prolific Machines has secured new investment led by Atoms & Bits and Nant Capital to scale its optogenetics biomanufacturing platform and announced partnerships with Zylidac Bio and NantWorks.
-
[BUSINESS] 2 sourcesMultiply Labs raises $75 million to scale robotic biomanufacturing
Multiply Labs raised $75 million in Series B funding to scale its robotic biomanufacturing platform for advanced medicines, including cell and gene therapies.
Sources
ma-clinique.fr · news-medical.net